A) Correct. The nurse should instruct the client to rotate injection sites to prevent lipohypertrophy, a condition characterized by fatty deposits at the injection sites that can affect insulin absorption.

B) Incorrect. Insulin should be injected into the subcutaneous tissue, not into the muscle. Injecting insulin into muscle can lead to faster absorption and potentially cause hypoglycemia.

C) Incorrect. Insulin should be stored in the refrigerator to maintain its potency. It should not be frozen or exposed to extreme heat.

D) Incorrect. Long-acting insulin and short-acting insulin should not be mixed in the same syringe unless specifically instructed by a healthcare provider. Mixing different types of insulin can alter their pharmacokinetics and effectiveness.

C) Correct. Levothyroxine sodium should be taken on an empty stomach, preferably 30 minutes to 1 hour before breakfast or at least 3-4 hours after the last meal. Food can interfere with the absorption of levothyroxine, reducing its effectiveness.

A) Incorrect. Taking levothyroxine before bedtime can disrupt sleep due to potential side effects, such as palpitations or insomnia.

B) Incorrect. Taking levothyroxine with meals can interfere with its absorption and reduce its effectiveness.

D) Incorrect. Levothyroxine should be taken at specific times to optimize its absorption and maintain consistent blood levels.

C) Correct. Corticosteroids can increase blood glucose levels and lead to hyperglycemia. The nurse should monitor the client's blood glucose levels closely and adjust the diabetes management plan accordingly.

A) Incorrect. Corticosteroids can cause hyperglycemia, not hypoglycemia.

B) Incorrect. Hypotension is not a common adverse effect of corticosteroids.

D) Incorrect. Hyperkalemia is not directly associated with corticosteroid use.

C) Correct. Metformin is known to cause gastrointestinal upset, including symptoms such as nausea, vomiting, diarrhea, and abdominal discomfort. The client should be advised to monitor for these adverse effects and report them to the healthcare provider if they occur.

A) Incorrect. Hypoglycemia is not a common adverse effect of metformin when used as a monotherapy. However, if metformin is used in combination with other antidiabetic medications that can cause hypoglycemia, the risk may increase.

B) Incorrect. Weight gain is not typically associated with metformin. In fact, metformin may be associated with weight loss or weight stabilization in some individuals.

D) Incorrect. Bradycardia is not a known adverse effect of metformin.

D) Correct. Glucocorticoid therapy can suppress the immune system, increasing the client's risk of infections and delaying wound healing. The nurse should monitor the client for signs of infection and educate the client about measures to prevent infection.

A) Incorrect. Hyperkalemia is not typically associated with glucocorticoid therapy. In fact, glucocorticoids can cause hypokalemia in some cases.

B) Incorrect. Hypotension is not a common adverse effect of glucocorticoid therapy.

C) Incorrect. Glucocorticoids can cause hypercalcemia, not hypocalcemia.

D) Correct. Levothyroxine sodium is used to treat hypothyroidism and aims to normalize thyroid hormone levels. However, excessive doses can lead to hyperthyroidism, characterized by symptoms such as tachycardia, palpitations, and tremors. The client should be instructed to report any signs of hyperthyroidism promptly.

A) Incorrect. Weight loss is a desired effect of levothyroxine therapy in individuals with hypothyroidism.

B) Incorrect. Constipation is a symptom associated with hypothyroidism and should improve with levothyroxine therapy.

C) Incorrect. Cold intolerance is a symptom associated with hypothyroidism and should improve with levothyroxine therapy.

A) Correct. Insulin lispro is a rapid-acting insulin with a rapid onset of action, typically within 15 minutes, and a short duration of action, lasting about 3-4 hours. It is used to control postprandial glucose levels.

B) Incorrect. Insulin lispro is not characterized by slow onset and long duration of action. This description more closely matches the characteristics of long-acting insulins.

C) Incorrect. Insulin lispro is not characterized by intermediate onset and duration of action. Intermediate-acting insulins, such as NPH insulin, have a slower onset and a longer duration of action.

D) Incorrect. Insulin lispro, like other insulins, has a peak action time. The peak action time refers to the time when the insulin has its maximum effect on lowering blood glucose levels.